Beta Drugs Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/8yjmspje7nd8pn4spzv3aaj2.pdf

Key Takeaways


The Nivian Bet: High Growth, Margin Upside Still to Come

Natarajan: "I think the guidance towards 25% EBITDA margins is very conservative, keeping in mind the factors that I just listed above."

Export Engine: Registrations Pipeline Is the Moat

Rahul Batra: "We want to guide low, but we want to deliver better."

Branded Business: Oncology Leads, Derma Builds, Platin Stalls

Rahul Batra: "Sometimes the requirement is for 5,000 vials, we are just feeding the market with 1,000 vials or 1,500 vials for that particular product."

Backward Integration: The Margin Story That Hasn't Yet Landed

Rahul Batra: "We have been doing CDMO business since last 15 years now, and any partner is associated with us, we have never lost them."

Strategic Bets Beyond FY30: Biosimilars, Local Manufacturing, Recombinants

Natarajan: "Our view is that we would want to take a business model which doesn't require capital commitment or rather limits our capital commitment upfront, and over a period of time, as the business gets established, we kind of double down on that business."

Financial Health: Debt Down, Receivables Up, Forex Neutral

Rahul Batra: "Even if the MRP goes down the realization will remain the same. The patient will be getting the benefit out of it."

Guidance & Commitments

CommitmentSpecificsTimeline
Overall revenue growth20–25% annual growth sustainedNext 3–5 years
EBITDA margin23–24% sustained; 25% described as "very conservative" targetSustained / aspirational
Own-brand salesINR150 croresFY27
Export revenueINR90–100 croresFY27
Export revenue~INR300 crores aggregateNext 3–4 years
Branded oncology growth20–22% (H1 was 17%)FY27
CMO revenueINR180–190 croresFY27
Nivian growth30–35% annual growthNext 2–3 years
Nivian EBITDA margin23–25% (from ~18–18.5% currently)As synergies flow
Intermediate plantGo liveJanuary 2027
API plant PIC/S approvalApproval received, enabling API exports1–2 months
EU GMP auditAudit letter expected2–4 months
New product launches6 more launches plannedRemaining months of FY27
Registrations received~50 registrationsFY27
Recombinant FSH launch at NivianProduct launch in Indian market2–3 years

Key Metrics

MetricQ2 FY27
Revenue growth29.2% YoY (H1 FY27 vs H1 FY26)
EBITDA margin23.18% (including other income), up 0.10 ppt YoY; 22% excluding other income
PAT₹34 cr (H1 FY27), up ~45% from ₹24 cr in H1 FY26
Own-branded business growth17% YoY (H1 FY27 vs H1 FY26)
Own-branded business FY27 target₹150 cr, >20% growth YoY; H2 expected at ₹80 cr vs ₹62 cr in H2 FY26
CMO business growth21% YoY (H1 FY27)
CMO business FY27 guidance₹180–190 cr
Exports revenue₹43 cr (H1 FY27), up from ₹16 cr base (ex-opportunity) in H1 FY26
API business growth30% YoY (H1 FY27 vs H1 FY26)
Nivian Lifesciences growth75% YoY (H1 FY27 vs H1 FY26), sales from ₹18 cr to ₹31 cr
Nivian FY26 revenue~₹43 cr
Derma PCPM₹2.5 lakhs average in H1 FY27, up 30% YoY
Total days receivable116 days as of Sep 2026, vs 113 days at Mar 2026
New registrations in pipeline872 registrations expected over next 2–3 years; 50 expected in FY27
Branded business impacted by plant shutdown₹6–7 cr sales shifted from Q2 to H2 due to debottlenecking